RESMED INC FY 2026: Revenue $5.65B, EPS $10.43— 10-K Summary
ResMed reported fiscal 2026 net revenue of $5.65B, up 9.9% from $5.15B, with net income of $1.52B and diluted EPS of $10.43, according to its FY2026 10-K. The company cited device and mask growth, gross margin rising to 61.1%, R&D of $378M, and moves including acquiring Noctrix and divesting MatrixCare.
How this was made
The 30-second read
Why it matters
Traders can use the reported revenue, EPS, margin, and portfolio actions to reassess earnings power and integration/divestiture impact, but the lack of explicit forward guidance limits immediate conviction.
Market read
A company-specific SEC filing summary with multiple concrete financial and portfolio datapoints that can inform valuation and positioning.
What to watch
The summary omits cash flow details, segment-level profitability, and any updated outlook, which are often the key drivers of post-filing repricing.
Background
The text is a brief summary of ResMed’s fiscal 2026 10-K filed Aug. 13, 2026, including financial highlights and business/product and portfolio updates.
Ticker impact
ResMed’s FY2026 10-K summary reports net revenue of $5.65B (+9.9% YoY), diluted EPS of $10.43, and gross margin rising to 61.1%.
Moderately positive bias for near-term sentiment, with follow-through depending on how investors interpret margin improvement and the impact of Noctrix/MatrixCare.
The article discloses multiple specific, decision-relevant datapoints from the company’s SEC filing, but it is a summary and does not include forward guidance or a fresh market-moving surprise beyond the filing itself.
Market effects
Highlights continued demand strength in sleep-disordered breathing devices and masks, reinforcing positive read-through for medical device/sleep diagnostics demand.
Americas (+9%) and Rest of World (+13%) growth suggests broad-based geographic momentum.
No direct macro linkage, but margin and portfolio moves can influence investor sentiment toward the sleep apnea device space.
Counterpoint
Margin improvement and device growth may already be anticipated; without explicit forward guidance, the market may focus on execution risk from the acquisition and divestiture.
Key entities
- companyResMed Inc
Reported FY2026 net revenue $5.65B (+9.9% YoY), diluted EPS $10.43, gross margin 61.1%, acquired Noctrix, and announced divestiture of MatrixCare.
- acquisition_targetNoctrix
Acquired to add an RLS device to ResMed’s sleep portfolio.
- divestiture_targetMatrixCare
Business announced for divestiture, held for sale.
- productAirSense 11
Launched with touchscreen, updated algorithms, and over-the-air updates.
